嵌合抗原受体
前药
细胞毒性T细胞
肿瘤微环境
癌症研究
抗原
T细胞
免疫系统
体内
免疫疗法
生物
化学
免疫学
体外
药理学
生物化学
生物技术
作者
Thomas J. Gardner,J. Peter Lee,Christopher M. Bourne,Dinali Wijewarnasuriya,Nihar Kinarivala,Keifer G. Kurtz,Broderick C. Corless,Megan M. Dacek,Aaron Y. Chang,George Mo,Kha M. Nguyen,Renier J. Brentjens,Derek S. Tan,David A. Scheinberg
标识
DOI:10.1038/s41589-021-00932-1
摘要
Chimeric antigen receptor (CAR)-T cells represent a major breakthrough in cancer therapy, wherein a patient’s own T cells are engineered to recognize a tumor antigen, resulting in activation of a local cytotoxic immune response. However, CAR-T cell therapies are currently limited to the treatment of B cell cancers and their effectiveness is hindered by resistance from antigen-negative tumor cells, immunosuppression in the tumor microenvironment, eventual exhaustion of T cell immunologic functions and frequent severe toxicities. To overcome these problems, we have developed a novel class of CAR-T cells engineered to express an enzyme that activates a systemically administered small-molecule prodrug in situ at a tumor site. We show that these synthetic enzyme-armed killer (SEAKER) cells exhibit enhanced anticancer activity with small-molecule prodrugs, both in vitro and in vivo in mouse tumor models. This modular platform enables combined targeting of cellular and small-molecule therapies to treat cancers and potentially a variety of other diseases. The synthetic enzyme-armed killer (SEAKER) approach equips chimeric antigen receptor (CAR)-T cells with the capacity to express enzymes that process anticancer prodrugs at tumor sites of action.
科研通智能强力驱动
Strongly Powered by AbleSci AI